Where Pharma Growth Is Coming From (Hospital vs Home vs Digital)

Why care setting is now a strategic variable

For decades, pharma commercial planning treated care setting as fixed. Hospital drugs went through the GPO channel; physician-office drugs through buy-and-bill; retail through pharmacies. That stability is gone. Subcutaneous reformulations, GLP-1 telehealth prescribing, home oncology infusion programs and hospital-at-home reimbursement codes have re-routed where billions of dollars of drugs actually get administered.

The three care settings. and how they’re moving

1. Hospital / inpatient. biggest, slowest-growing

Hospitals still account for ~40% of pharma revenue (oncology, anti-infectives, ICU drugs, complex biologics). Growth is modest (3, 5% CAGR) and is structurally constrained by capacity and reimbursement.

Strategic pressure: 340B program scrutiny, GPO consolidation, and inpatient DRG bundling all compress hospital pharma margins.

2. Home / self-administration. fastest-growing

Home is the channel exploding right now. Drivers:

• GLP-1 weekly injectables: >10 million US patients self-administer weekly.
• Subcutaneous reformulations of IV biologics: Tezspire, Tecentriq, Phesgo. moving infusion from clinic to home / short-stay.
• Home infusion contracts: CMS expanded home infusion benefits in 2024.
• Hospital-at-home programs: 300+ approved sites in the US deliver inpatient-level care at home.

Result: home channel growth is 12, 18% CAGR, with major tailwinds extending through 2030.

3. Digital-first care. restructuring chronic disease

Telehealth and asynchronous prescribing models (Hims, Ro, Noom-Rx, Hey Ozempic clones, employer telehealth) now drive a meaningful share of GLP-1, ED, derm, mental health and HIV PrEP prescriptions. The implications for pharma:

• Direct-to-consumer demand generation works again (after a decade of regulatory caution).
• Adherence data is digital-first. you get patient-level engagement metrics within days, not quarters.
• Branded experience competes with generics on convenience, not just efficacy.

Care setting share. pharma revenue mix

Sources: IQVIA Channel Dynamics, CMS, Definitive Healthcare, company reports.

What this means for commercial strategy

1. Reformulation is now strategic, not lifecycle-management. Subcutaneous and oral versions unlock the home channel and protect from biosimilar erosion.
2. Build digital prescribing partnerships early. Telehealth platforms have replaced field sales for several categories.
3. Re-think payer engagement. Home infusion and hospital-at-home have separate reimbursement codes. your access strategy must follow the molecule into the home.
4. Don’t abandon hospital. Hospital is slow-growing but high-margin. The mistake is over-rotating to digital before the hospital franchise is defended.

The decision question

For each asset in your pipeline, ask: “Does this drug naturally belong in the home, the clinic or the hospital. and is our commercial machine optimized for that channel?” The teams that match molecule-to-channel correctly are the ones whose Y3-Y5 launch revenue beats consensus.

Frequently Asked Questions

Which care setting is growing fastest for pharma?

Home / self-administration is the fastest-growing channel at 12, 18% CAGR, driven by GLP-1 self-injection, subcutaneous biologic reformulations, expanded CMS home infusion benefits and hospital-at-home programs.

Is the hospital channel declining?

No. hospital remains the largest channel (~40% of pharma revenue) and is still growing 3, 5% CAGR. But its share is shrinking as home and digital grow faster. Hospital is best understood as “stable but slow”.

How is digital-first care changing pharma commercial?

Telehealth and asynchronous prescribing now drive significant share in GLP-1, derm, mental health and HIV PrEP. This restores DTC demand-generation effectiveness, provides patient-level adherence data, and lets brands compete on convenience.

What should pharma commercial teams do about care setting shifts?

Treat reformulation as strategic (not LCM), partner with telehealth platforms, build setting-specific reimbursement strategies (especially home infusion), and match each asset to the right channel before launch.

References & Further Reading

• CMS — Home Infusion Therapy Benefit
• IQVIA — Channel Dynamics
• Definitive Healthcare — Care Setting Trends
• CMS — Acute Hospital Care at Home Program

Related decisions to read next

• Global Pharma Market Segmentation by Therapy + Modality
• Emerging Pharma Markets Investors Are Betting On
• Which Therapy Areas Are Overcrowded vs Underinvested

Take the next decision

This brief is part of the Pharma & Biotech Decision Intelligence hub at Widelly. It is built for strategy, BD and investor teams who need to convert live healthcare data into defensible decisions.